Medication utilization for targeted symptoms in children and adults with fragile X syndrome: US survey

Journal of Developmental and Behavioral Pediatrics

Volumn 33, Issue 1, 2012, Pages 62-69

  Bailey Jr , Donald B ^a   Raspa, Melissa ^a   Bishop, Ellen ^a   Olmsted, Murrey ^a   Mallya, Usha G ^b   Berry Kravis, Elizabeth ^c  

^a RTI INTERNATIONAL   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Fragile X Syndrome; medication treatments; pill swallowing

Indexed keywords

ADULT; ANXIETY; ATTENTION; ATTENTION DEFICIT DISORDER; CHILD; DRUG EFFECT; FEMALE; FRAGILE X SYNDROME; HEALTH SURVEY; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SWALLOWING; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, ORAL; ADULT; ANXIETY; ATTENTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DEGLUTITION; FEMALE; FRAGILE X SYNDROME; HEALTH SURVEYS; HUMANS; MALE; TREATMENT OUTCOME; UNITED STATES;

EID: 84855455842     PISSN: 0196206X     EISSN: None     Source Type: Journal    
DOI: 10.1097/DBP.0b013e318236c0e1     Document Type: Review

References (32)

1. Hall SS, Burns DD, Lightbody AA, Reiss AL. Longitudinal changes in intellectual development in children with fragile X syndrome. J Abnorm Child Psychol. 2008;36:927-939.
2. Loesch DZ, Huggins RM, Hagerman RJ. Phenotypic variation and FMRP levels in fragile X. Ment Retard Dev Dis Res Rev. 2004;10: 31-41. (Pubitemid 38375351)
3. Bailey DB, Raspa M, Olmsted M, Holiday DB. Co-occurring conditions associated with FMR1 gene variations: Findings from a national parent survey. Am J Med Genet Part A. 2008;146A: 2060-2069.
4. Berry-Kravis E, Raspa M, Loggin-Hester L, Bishop E, Holiday D, Bailey DB. Seizures in fragile X syndrome: Characteristics and co-morbid diagnoses. Am J Intellect Dev Disabil. 2010;115:461-472.
5. Amaria RN, Billeisen LL, Hagerman RJ. Medication use in fragile X syndrome. Ment Health Aspects Dev Disabil. 2001;4:143-147. (Pubitemid 34007454)
6. Berry-Kravis E, Potanos K. Psychopharmacology in fragile X syndrome-present and future. Ment Retard Dev Disabil Res Rev. 2004;10:42-48.
7. Valdovinos MG, Parsa RA, Alexander ML. Results of a nationwide survey evaluating psychotropic medication use in fragile X syndrome. J Dev Phys Disabil. 2009;21:223-237.
8. Hagerman RJ, Murphy MA, Wittenberger MD. A controlled trial of stimulant medication in children with the fragile X syndrome. Am J Med Genet. 1988;30:377-392.
9. Berry-Kravis E, Sumis A, Hervey C, et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr. 2008;29:293-302.
10. Erickson CA, Weng N, Weiler IJ, et al. Open-label riluzole in fragile X syndrome. Brain Res. 2011;1380:264-270.
11. Hagerman RJ, Riddle JE, Roberts LS, Breese K, Fulton M. A survey of the efficacy of clonidine in fragile X syndrome. Dev Brain Dysfunct. 1995;8:336-344. (Pubitemid 26150616)
12. Hagerman RJ, Fulton MJ, Leaman A, Riddle J, Hagerman K, Sobesky W. Fluoxetine therapy in fragile X syndrome. Dev Brain Dysfunct. 1994;7:155-164.
13. Hall SS. Treatments for fragile X syndrome: A closer look at the data. Dev Disabil Res Rev. 2009;15:353-360.
14. Dolen G, Carpenter RL, Ocain TD, Bear MF. Mechanism-based approaches to treating fragile X. Pharmacol Ther. 2010;127: 78-93.
15. Hagerman RJ, Berry-Kravis E, Kaufmann WE, et al. Advances in the treatment of fragile X syndrome. Pediatrics. 2009;123:378-390.
16. de Vrij FM, Levenga J, van der Linde HC et al. Rescue of behavioral phenotype and neuronal protrusion morphology in FMR1 KO mice. Neurobiol Dis. 2008;31:127-132. (Pubitemid 351822560)
17. Chang S, Bray SM, Li Z, et al. Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat Chem Biol. 2008;4:256-263. (Pubitemid 351419125)
18. Paribello C, Tao L, Folino A, et al. Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol. 2010; 10:91.
19. Berry-Kravis E, Hessl D, Coffey S, et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet. 2009;46:266-271.
20. Wetmore DZ, Garner CC. Emerging pharmacotherapies for neurodevelopmental disorders. J Dev Behav Pediatr. 2010;31: 564-581.
21. Jacquemont S, Curie A, des Portes V, et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med. 2011;3:64ra1.
22. Berry-Kravis E, Sumis A, Kim OK, Lara R, Wuu J. Characterization of potential outcome measures for future clinical trials in fragile X syndrome. J Autism Dev Disord. 2008; 38:1751-1757.
23. Polaha J, Dalton WT, Lancaster BM. Parental report of medication acceptance among youth: Implications for everyday practice. South Med J. 2008;101:1106-1012.
24. Meltzer EO, Welch MJ, Ostrom NK. Pill swallowing ability and training in children 6-11 years of age. Clin Pediatr (Phila). 2006;45:725-733. (Pubitemid 44359192)
25. Beck MH, Cataldo M, Slifer KJ, Pulbrook V, Guhman JK. Teaching children with attention deficit hyperactivity disorder (ADHD) and autistic disorder (AD) how to swallow pills. Clin Pediatr (Phila). 2005;44:515-526. (Pubitemid 40967693)
26. Ghuman JK, Cataldo MD, Beck MH, Slifer KJ. Behavioral training for pill-swallowing difficulties in young children with autistic disorder. J Child Adolesc Pschopharmacol. 2004;14:601-611.
27. Kaplan BJ, Steiger RA, Pope J, Marsh A, Sharp M, Crawford SG. Successful treatment of pill-swallowing difficulties with head posture practice. Paediatr Child Health. 2010;15:e1-e5.
28. Bailey DB, Raspa M, Olmsted MG. Using a parent survey to advance knowledge about the nature and consequences of fragile X syndrome. Am J Intellect Dev Disabil. 2010;115:447-460.
29. Symons FJ, Byiers BJ, Raspa M, Bishop E, Bailey DB. Selfinjurious behavior and fragile X syndrome: Findings from the National Fragile X Survey. Am J Intellect Dev Disabil. 2010;115(6):473-481.
30. Kronk R, Bishop E, Raspa M, Bickel JO, Mandel DA, Bailey DB. Prevalence, nature, and correlates of sleep problems in fragile X syndrome. Sleep. 2010;33:679-687.
31. Aman MG, Marks RE, Turbott SH, Wilsher CP, Merry SN. The clinical effects of methylphenidate and thioridazine in intellectually subaverage children: Effects of cognitive motor performance. J Am Acad Child Adolesc Psychiatry. 1991;30: 246-256.
32. Handen BL, Janosky J, McAuliffe S. Long-term follow up of children with mental retardation/borderline intellectual functioning and ADHD. J Abnorm Child Psychol. 1997;25:287-295. (Pubitemid 27391286)